Literature DB >> 10537328

Prostate-specific membrane antigen is produced in tumor-associated neovasculature.

S S Chang1, D S O'Keefe, D J Bacich, V E Reuter, W D Heston, P B Gaudin.   

Abstract

Prostate-specific membrane antigen (PSMA), a type II transmembrane protein, was originally thought to be strictly expressed in prostatic tissue, but recent studies have demonstrated PSMA protein expression in nonprostatic tumor neovasculature as well. Using immunohistochemistry, reverse transcription-PCR assays, and in situ hybridization, we have demonstrated PSMA mRNA transcripts and protein expression in the endothelium of tumor-associated neovasculature of multiple nonprostatic solid malignancies. In addition, we found no PSMA mRNA or protein expression in the vascular endothelial cells of corresponding benign tissue examples. Our findings expand the possible therapeutic role of PSMA and establish it as a unique biomarker specifically produced and expressed by tumor-associated neovasculature but not produced or expressed by normal vessels.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10537328

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  146 in total

1.  Immunocapture of prostate cancer cells by use of anti-PSMA antibodies in microdevices.

Authors:  Steven M Santana; He Liu; Neil H Bander; Jason P Gleghorn; Brian J Kirby
Journal:  Biomed Microdevices       Date:  2012-04       Impact factor: 2.838

Review 2.  Molecular targeting of angiogenesis for imaging and therapy.

Authors:  Simon S Brack; Ludger M Dinkelborg; Dario Neri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-08-05       Impact factor: 9.236

3.  2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.

Authors:  Ying Chen; Mrudula Pullambhatla; Catherine A Foss; Youngjoo Byun; Sridhar Nimmagadda; Srinivasan Senthamizhchelvan; George Sgouros; Ronnie C Mease; Martin G Pomper
Journal:  Clin Cancer Res       Date:  2011-10-31       Impact factor: 12.531

4.  [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH.

Authors:  A Afshar-Oromieh; U Haberkorn; M Eder; M Eisenhut; C M Zechmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02-04       Impact factor: 9.236

Review 5.  Strategies in the design of nanoparticles for therapeutic applications.

Authors:  Robby A Petros; Joseph M DeSimone
Journal:  Nat Rev Drug Discov       Date:  2010-07-09       Impact factor: 84.694

Review 6.  GCPII imaging and cancer.

Authors:  C A Foss; R C Mease; S Y Cho; H J Kim; M G Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

7.  Molecular imaging of glutamate-carboxypeptidase II (prostate-specific membrane antigen) in malignant epithelioid hemangioendothelioma.

Authors:  Thorsten Derlin; Ulrich Baumann; Frank M Bengel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-12       Impact factor: 9.236

8.  Substrate specificity of prostate-specific membrane antigen.

Authors:  Marc O Anderson; Lisa Y Wu; Nicholas M Santiago; Jamie M Moser; Jennifer A Rowley; Erin S D Bolstad; Clifford E Berkman
Journal:  Bioorg Med Chem       Date:  2007-08-11       Impact factor: 3.641

Review 9.  Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer.

Authors:  Steven P Rowe; Alexander Drzezga; Bernd Neumaier; Markus Dietlein; Michael A Gorin; Michael R Zalutsky; Martin G Pomper
Journal:  J Nucl Med       Date:  2016-10       Impact factor: 10.057

Review 10.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.